Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $38.00

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $38.00.

A number of research firms recently weighed in on INO. HC Wainwright decreased their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th. Oppenheimer decreased their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. Finally, Royal Bank of Canada cut their price target on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday, November 15th.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its position in shares of Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 3,630 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at approximately $71,000. The Manufacturers Life Insurance Company acquired a new stake in Inovio Pharmaceuticals during the 2nd quarter valued at $82,000. Signature Estate & Investment Advisors LLC purchased a new position in Inovio Pharmaceuticals during the second quarter worth $88,000. Finally, MetLife Investment Management LLC raised its holdings in shares of Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 8,546 shares during the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ:INO opened at $2.32 on Thursday. The company has a 50-day moving average price of $4.89 and a 200 day moving average price of $7.13. Inovio Pharmaceuticals has a 52 week low of $2.14 and a 52 week high of $14.75.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.